CPhI Worldwide Launches Charity Initiative with Global Angels

Article

A range of packages is available for industry partners to implement charity giving.

CPhI Worldwide has launched a new partnership with the international charity Global Angels in a move to encourage support from the pharmaceutical industry. Global Angels partners with innovative projects to deliver tangible, life-saving results in developing countries.

CPhI’s goal is to actively provide support and funds from the pharma industry to Global Angels. Pharma companies can help the charity through direct funding, volunteering, providing logistical support, or donating vital drugs to the developing world. According to CPhI, the initiative is already showing signs of success, with many companies registering their interest.

CPhI is offering two corporate social responsibility packages-“Angel Wings” and “Angel Logo”-that allow exhibitors or industry partners to get involved more quickly with Global Angels. The “Angel Wing”’ package is a direct charity funding initiative where donations from industry partners will be used to pay for cleft lip surgery, child food support, funding for a water well, or even help build a classroom or a rural hospital.

The “Angel Logo” program provides free advertising for any charity sponsor through CPhI’s global events portfolio. CPhI will provide advertising support to industry donors through a range of promotional options such as display and print advertising to live videos during the event, with a potential captive audience of 500,000 pharmaceutical professionals and industry press.

CPhI is encouraging exhibitors and visitors to contribute when booking their space or registering for the event. To find out more on how you or your business can help support this charity or to donate to Global Angels, please visit www.cphi.com/angels.

 

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content